Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. - Wikidata - awgldk - TriplyDB

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

http://www.wikidata.org/entity/Q36242608

about

Carotid artery intima-media thickness and the renin-angiotensin system Vasculopathy of Aging and the Revised Cardiovascular Continuum Multivariate risk assessment and risk score cards in hypertension The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy.Nifedipine and telmisartan for the treatment of hypertension: the TALENT study.Renin-angiotensin system blocking drugs.Perindopril may improve the hippocampal reduced glutathione content in rats.Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): similarities and differences.Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice.Angiotensin receptor blockers and endpoint protection.2007 ESH‐ESC Guidelines for the management of arterial hypertension A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers i

P2860

Q26851516-5EDA486A-B6D0-4F39-8876-FC9765F023C2 Q26851569-C25B89CF-A152-4692-9847-7E652CE60953 Q28219606-81A573D4-8899-49CF-8361-FE2223422B7F Q37218795-FC726875-BCD0-42E0-A307-3586F050BA93 Q37959050-9F750372-AE0C-40C8-A3A9-14D9E2EA9500 Q38137851-1F011143-1FDB-4501-901C-11E28620A0AD Q41870373-6E4E678A-71E9-4C15-A961-F67D9B3CA4A0 Q42032779-6D8FCDC5-F3F9-4E52-B3C0-E45EE8D1DE97 Q51471682-0E81CE04-5C30-4CC8-9F59-DAFE8291479F Q53752471-076E4228-2BA9-42E1-9540-4F54C6463666 Q53845954-1BBE020B-17EC-4B69-83FE-C3475C4CEA12 Q56970799-4CF2ACE0-F739-42C5-9290-7051F39BC532 Q59136772-24C6D1B5-D94B-4486-8FEF-E5B963F13CEF

P2860

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

http://www.wikidata.org/entity/Q36242608

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

@ast

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

@en

type

label

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

@ast

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

@en

prefLabel

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

@ast

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

@en

P1433

Q36242608-C91320EE-C15A-493F-91A6-F9F6DE771CE8

P1476

Q36242608-D58F644A-A7F6-47DF-98EF-A9349E5DEFE2

P2093

Q36242608-1F5B8D17-E087-4BB3-A285-18E7287465DE

Q36242608-348DFA7D-BF5A-4FE0-ACD8-FA88A23CCE57

Q36242608-45CC5A10-8453-40F6-B1B7-AFA5FEECA248

Q36242608-B4EBD398-215A-42C7-A706-9CFA9D78654F

Q36242608-D0CEA997-687A-4709-ADD8-1F5FCFF442E4

P2860

Q36242608-03165180-25E3-4579-8DE0-7F52B865D869

Q36242608-0B82B705-F070-4EC7-8595-F937633E3F85

Q36242608-0C57D7C2-9A75-405E-A29A-5135A81A730E

Q36242608-0D4676A2-B3AD-4EE6-92E3-CBA3EE42F064

Q36242608-0FEFC585-0872-438A-997E-256C6986BF37

Q36242608-10912F12-5AB5-4B90-BF86-0E6C77A2BCB5

Q36242608-18104017-2C71-4A32-B6AD-2939A9ED1FF1

Q36242608-18FB4939-2158-4749-9733-56E0588BDF04

Q36242608-1958F410-0B13-4A8A-869C-2A345BF2147A

Q36242608-19955B8B-B666-4C91-BCB2-6A9E4D0A60F6

P304

Q36242608-2D3D2E86-E47C-4A9F-A043-A0394A8636B5

P31

Q36242608-D1A08B49-8712-4E2E-BD73-DBF67B6C0BDD

P356

Q36242608-D0D4EEA3-5852-4A36-803B-701A1300335B

P433

Q36242608-FCD68C19-2343-4848-9953-153AE488E5F3

P478

Q36242608-8D198C26-64C2-4355-8115-878C3E0B2A9C

P50

Q36242608-0386C9FE-CA48-40DD-88B3-DD083B1AE248

Q36242608-3BE189BF-A75B-4565-AF50-8C406BAB12CB

Q36242608-50B604DF-D0AF-474A-9893-EC5231EFE1DD

Q36242608-852DD6EF-5081-4A9C-B73F-71CDFC79F4E2

Q36242608-A2BCD561-BC10-4608-AF97-1ED75B1492A6

P577

Q36242608-97DBFFFB-ACEA-4457-A187-4977405E178B

P698

Q36242608-B9C26C47-532B-4AB0-843B-8AC832B6EB49

P356

08037050500230227

P1433

P1476

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

@en

P2093

Bernard Waeber

http://www.w3.org/2001/XMLSchema#string

Enrico Agabiti Rosei

http://www.w3.org/2001/XMLSchema#string

George L Bakris

http://www.w3.org/2001/XMLSchema#string

Neil R Poulter

http://www.w3.org/2001/XMLSchema#string

Stefano Taddei

http://www.w3.org/2001/XMLSchema#string

P2860

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Global burden of hypertension: analysis of worldwide data

Global and societal implications of the diabetes epidemic

Selected major risk factors and global and regional burden of disease

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

P304

196-209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/08037050500230227

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Mancia

Luis Miguel Ruilope

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16126553

http://www.w3.org/2001/XMLSchema#string